Pfizer Inc.
PFEPfizer Inc. is a global pharmaceutical company known for its research and development of innovative medicines and vaccines. Founded in 1849, it has a diverse portfolio that includes treatments for various medical conditions, and it played a key role in developing one of the first COVID-19 vaccines. Pfizer operates in multiple healthcare sectors, including biopharmaceuticals, oncology, and immunology.
Dividend History
Investors can expect a dividend payout of $0.43 per share, scheduled to be distributed in 45 days on September 1, 2026
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 1, 2026 | $0.43 | 2026-07-24 | 2026-07-24 |
| June 12, 2026 | $0.43 | 2026-05-08 | 2026-05-08 |
| March 6, 2026 | $0.43 | 2026-01-23 | 2026-01-23 |
| December 1, 2025 | $0.43 | 2025-11-07 | 2025-11-07 |
| September 2, 2025 | $0.43 | 2025-07-25 | 2025-07-25 |
Dividends Summary
- Consistent Payer: Pfizer Inc. has rewarded shareholders with 91 dividend payments over the past 22 years.
- Total Returned Value: Investors who held PFE shares during this period received a total of $27.45 per share in dividend income.
- Latest Payout: The most recent dividend of $0.43/share was paid 36 days ago, on June 12, 2026.
- Yield & Schedule: PFE currently pays dividends quarterly with an annual yield of 6.87%.
- Dividend Growth: Since 2004, the dividend payout has grown by 152.9%, from $0.17 to $0.43.
- Dividend Reliability: PFE has maintained or increased its dividend for 70 consecutive payments.
Company News
The New Civil Liberties Alliance filed an amicus curiae brief with the U.S. Supreme Court in the Boysen v. PeaceHealth case, arguing that courts have misinterpreted the 1905 Jacobson v. Massachusetts decision to justify broad vaccine mandates. NCLA contends that Jacobson should only permit mandates when vaccines prevent disease transmission to th...
ResearchAndMarkets.com released a comprehensive report analyzing 1,230+ bioinformatics collaboration and licensing deals from 2019-2026, providing detailed benchmarking of upfronts, milestones, and royalty structures. The report serves as a reference for understanding how partnerships are structured in data-driven and platform-based transactions ...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
The global oral obesity therapies market is projected to grow from $4.32 billion in 2026 to $6.32 billion by 2030, with a compound annual growth rate of 9.9%. The market expansion is driven by increasing demand for GLP-1 treatments, combination therapies, personalized metabolic treatments, and telehealth-enabled prescribing. Key opportunities inc...
Pfizer's 7.1% dividend yield is the highest in the S&P 500, more than six times the average, raising concerns about sustainability. While the dividend currently appears safe with the company undergoing cost-cutting restructuring, earnings provide limited buffer with diluted per-share profit of $0.47 barely exceeding the quarterly dividend of $0.4...
